Amgen is claiming phase 2 victory for its prioritized bibispecific T-cell engager (BiTE), saying tarlatamab spurred durable response rates in patients with small cell lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,